Development of an oncolytic virotherapy targeting relapsed/refractory Ph+ leukemias

我们开发了一种溶瘤病毒疗法，通过这种疗法，病毒在肿瘤内感染和复制，并通过自然发生的过程导致细胞死亡。难治性血液系统恶性肿瘤，如Ph阳性白血病，是这种疗法的良好候选者。其中，多发性骨髓瘤对痘苗病毒表现出极高的敏感性。为了提高其安全性，我们研制了一种具有TK缺失和miRNA调控的多调控痘苗病毒。利用小鼠骨髓瘤移植模型，我们证实了病毒选择性有效地感染肿瘤并缩小了肿瘤的大小。这些数据表明，多调控痘苗病毒将成为未来溶瘤病毒治疗的一种有前途的工具。

We developed an oncolytic virotherapy, by which a virus infects and replicates within the tumor and leads to cell death via the naturally occurring process. Refractory hematological malignancies, such as Ph-positive leukemias, are good candidates for this therapy. Among them, multiple myeloma showed an exceptionally high sensitivity to vaccinia virus. To improve its safety, we made a multi-regulated vaccinia virus, which has TK-deletion and miRNA-regulation. Using a mouse myeloma transplantation model, we confirmed that the virus selectively and effectively infects tumor and reduces the tumor size. These data suggests that the multi-regulated vaccinia virus will be a promising tool for the future oncolytic virotherapy.